" class="no-js "lang="en-US"> Anat Cohen-Dayag - Medtech Alert
Saturday, September 30, 2023
Anat Cohen-Dayag

Anat Cohen-Dayag

About Anat Cohen-Dayag

Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&D and executive leadership roles. Since 2010, Dr. Cohen-Dayag has served as President and CEO of Compugen, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery. Under her leadership, Compugen underwent a strategic transformation to become a therapeutic discovery and development company utilizing its computational discovery expertise to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Dr. Cohen-Dayag holds an MS in Chemical Immunology and a PhD in Cellular Biology, both from the Weizmann Institute of Science.

Related Story

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

September 13 2022

Compugen Ltd. ( Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced […]

Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment

March 22 2022

Compugen Ltd. (Nasdaq: CGEN), (“Compugen,” the “Company”), a clinical-stage cancer immunotherapy company and a pioneer in computational […]

Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Million Equity Investment

November 11 2021

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today […]